Safe, effective, short-term glucose control seen in MK-0941 users

12/1/2011 | PhysiciansBriefing.com

Type 2 diabetes patients on stable-dose insulin glargine who used the glucokinase inhibitor MK-0941 had better A1C and two-hour post-meal glucose levels at week 14, compared with those who took a placebo, according to a study in Diabetes Care. However, researchers found that such improvements in glycemic control were not sustained by 30 weeks.

View Full Article in:

PhysiciansBriefing.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Principal Engineer - Service (US/MI/00/0043/SL) - 14000009CP
Abbott
Chicago, IL
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC